Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease and Wohlfart-Disease), Drug Type (Riluzole, Edaravone (Radicava) and Others), Distribution Channel (Hospital Pharmacies, and Retail and Online Pharmacies), Treatment type (Chemotherapy and Stem Cell Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Size
The global amyotrophic lateral sclerosis (ALS) treatment market is expected to experience steady growth in the coming years. ALS is a rare disease, but its prevalence is increasing globally, which is driving the demand for ALS treatments. Advances in technology have led to the development of new treatment options for ALS, which is expected to drive market growth. Growing awareness of ALS and better diagnosis of the disease are also driving the market growth. The pharmaceutical industry is investing heavily in research and development to develop new treatments for ALS, which is driving market growth
Data Bridge Market Research analyses that the global amyotrophic lateral sclerosis (ALS) treatment market which was USD 664.12 million in 2022, is expected to reach USD 1,034.12 million by 2030, and is expected to undergo a CAGR of 4.6% during the forecast period of 2023 to 2030. “Benign Focal Amyotrophy of ALS” dominates the product type segment of the global amyotrophic lateral sclerosis (ALS) Treatment market due to advancements in prenatal imaging and diagnosis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease and Wohlfart-Disease), Drug Type (Riluzole, Edaravone (Radicava) and Others), Distribution Channel (Hospital Pharmacies, and Retail and Online Pharmacies), Treatment type (Chemotherapy and Stem Cell Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), BrainStorm Cell Limited (Israel), Mylan N.V. (U.S.), Ionis Pharmaceuticals (U.S.), Biogen (U.S.), Covis Pharma (U.S.), Apotex Inc. (Canada), Ascend Laboratories LLC (U.S.), ITF Pharma (U.S.), Genervon Biopharmaceuticals, LLC (U.S.), Bausch Health Companies Inc. (Canada), ORPHAZYME A/S (Denmark), Orion Pharma Ltd. (Finland), KRINGLE PHARMA, INC. (U.S.), Amylyx Pharmaceuticals Inc (U.S.), Sun Pharmaceutical Industries Ltd. (India), Advanz Pharmaceutical (U.K.), Otsuka Pharmaceutical Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Amyotrophic lateral sclerosis (ALS) is also referred to as Lou Gehrig's disease. It is a progressive neurodegenerative disease in which nerve cells in the central nervous system that regulate voluntary muscles are damaged. Muscle twitching, stiff muscles, and weakness owing to a decrease in the size of muscles in the legs or arms are some of the common symptoms of this disease. The most prevalent type of motor neuron disease is ALS, which causes the body's cells to deteriorate and die, leaving the brain unable to regulate voluntary movements. ALS patients may lose the ability to swallow, breathe, speak, walk, and use their hands in about half of the cases.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
Drivers
- Advancements in ALS Research
The continuous progress in ALS research has been a fundamental driver in the quest for effective treatments. Scientists have made significant strides in unraveling the complex mechanisms underlying ALS, including genetic factors and molecular pathways. As our understanding of the disease deepens, researchers are better equipped to identify potential drug targets and innovative therapeutic approaches. This knowledge has not only accelerated drug development but has also paved the way for precision medicine strategies tailored to specific subtypes of ALS. The cumulative effect of these advancements is a more robust pipeline of potential treatments, offering hope for improved outcomes and a growing ALS treatment market.
- Rising Prevalence of ALS
While ALS remains a rare disease, there is evidence of a gradual increase in its prevalence worldwide. This rise can be attributed to several factors, including aging populations and potential environmental influences. As more individuals are diagnosed with ALS, there is a corresponding uptick in the demand for effective treatments. Healthcare systems and providers are confronted with the challenge of managing a growing patient population, necessitating the development and accessibility of ALS therapies. This trend underpins the market's growth potential as it responds to the increasing needs of ALS patients.
- Collaborative Research Initiatives
Collaboration among research institutions, pharmaceutical companies, and patient advocacy groups has played a pivotal role in advancing ALS treatment development. The complexity of ALS necessitates multidisciplinary efforts, and these collaborative initiatives foster a supportive ecosystem for research and drug discovery. Partnerships facilitate the pooling of knowledge, resources, and expertise, leading to more efficient clinical trials and an expedited timeline for introducing new therapies to the market. The collaborative spirit in ALS research not only accelerates progress but also enhances the overall competitiveness of the ALS treatment market.
Opportunities
- Precision Medicine Approaches for ALS
The advent of precision medicine represents a significant opportunity in the ALS treatment market. Precision medicine tailor’s treatments to individual patients based on their genetic makeup, disease subtype, and specific biomarkers. As our understanding of ALS genetics and molecular mechanisms deepens, the development of personalized therapeutic strategies gains momentum. This approach aims to optimize treatment efficacy while minimizing adverse effects. By embracing precision medicine, the ALS treatment market has the potential to offer more targeted and effective interventions, improving the lives of ALS patients.
- Emerging Therapeutic Modalities for ALS
The emergence of innovative therapeutic modalities is reshaping the landscape of ALS treatment. This includes gene therapy, RNA-based therapeutics, and other cutting-edge approaches. These modalities hold promise in addressing the genetic components of ALS, particularly in cases with identified genetic mutations. As research progresses and clinical trials advance, these novel treatments are expected to expand the market's portfolio. The ALS treatment market can capitalize on these emerging modalities to diversify treatment options and enhance the prospects of slowing disease progression and improving patient outcomes.
Restraints/Challenges
- Limited Treatment Options for ALS
One of the fundamental challenges in the ALS treatment landscape is the limited availability of curative therapies. ALS remains a devastating neurodegenerative disease without a definitive cure. Currently, the treatments primarily focus on symptom management, quality of life improvements, and the deceleration of disease progression. While these treatments are vital in enhancing the well-being of ALS patients, they do not offer a complete remedy. This limitation can be a significant restraint in the ALS treatment market as the absence of curative options underscores the urgency of ongoing research and development efforts.
- Limited Availability Biomarkers for ALS
A significant challenge in the ALS treatment market is the scarcity of reliable biomarkers for disease diagnosis, prognosis, and treatment response. Biomarkers play a crucial role in monitoring disease progression and assessing treatment efficacy. Their absence poses a hindrance to the development of targeted therapies and personalized treatment strategies. The challenge ahead involves intensive research efforts to identify and validate robust biomarkers that can reliably inform treatment decisions and provide valuable insights into ALS progression.
This global amyotrophic lateral sclerosis (ALS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global amyotrophic lateral sclerosis (ALS) treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, Mitsubishi Tanabe Pharma America, Inc. a subsidiary of Mitsubishi Chemical Holdings Corporation announced that RADICAVA ORS (edaravone) is now available in the U.S. for the treatment of amyotrophic lateral sclerosis (ALS)
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Scope
The global amyotrophic lateral sclerosis (ALS) treatment market is segmented on the basis of disease type, drug type, distribution channel, treatment type and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Benign Focal Amyotrophy of ALS
- Infantile Spinal Muscular Atrophy
- Juvenile Spinal Muscular Atrophy
- Kugelberg-Welander Disease
- Primary Lateral Sclerosis
- Progressive Bulbar Palsy
- Spinal Muscular Atrophy
- Upper Motor Neuron Disease
- Werdnig-Hoffman Disease
- Wohlfart-Disease
Drug Type
- Riluzole
- Edaravone (Radicava)
- Others
Treatment Type
- Chemotherapy
- Stem Cell Therapy
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Regional Analysis/Insights
The global amyotrophic lateral sclerosis (ALS) treatment market is analysed and market size insights and trends are provided by country, disease type, drug type, distribution channel, treatment type and end user as referenced above.
The countries covered in the global amyotrophic lateral sclerosis (ALS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global amyotrophic lateral sclerosis (ALS) treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to because of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global amyotrophic lateral sclerosis (ALS) treatment market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global amyotrophic lateral sclerosis (ALS) treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global amyotrophic lateral sclerosis (ALS) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global amyotrophic lateral sclerosis (ALS) treatment market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Analysis
The global amyotrophic lateral sclerosis (ALS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global amyotrophic lateral sclerosis (ALS) treatment market.
Some of the major players operating in the global amyotrophic lateral sclerosis (ALS) treatment market are:
- Sanofi (U.S.)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- BrainStorm Cell Limited (Israel)
- Mylan N.V. (U.S.)
- Ionis Pharmaceuticals (U.S.)
- Biogen (U.S.)
- Covis Pharma (U.S.)
- Apotex Inc. (Canada)
- Ascend Laboratories LLC (U.S.)
- ITF Pharma (U.S.)
- Genervon Biopharmaceuticals, LLC (U.S.)
- Bausch Health Companies Inc. (Canada)
- ORPHAZYME A/S (Denmark)
- Orion Pharma Ltd. (Finland)
- KRINGLE PHARMA, INC. (U.S.)
- Amylyx Pharmaceuticals Inc (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Advanz Pharmaceutical (U.K.)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
SKU-